Non-nucleoside reverse transcriptase inhibitors
CA 2496565 C · Owner: Ardea Biosciences, Inc. · Inventors: Nilar, Shahul; Gunic, Esmir; Girardet, Jean-Luc
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 22, 2003 and granted April 2, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.